Cameron’s Law changes federal tax treatment for drugs designated to treat rare diseases by restoring the statutory rate used to calculate the orphan drug tax credit. The bill targets the specific line in the Internal Revenue Code that sets how much of qualifying clinical testing expenses can be claimed as a credit.
That change matters to drug developers, investors, and tax planners: a higher credit increases the after‑tax return from clinical programs for rare-disease indications, shifting the economics of when companies decide to pursue those indications and potentially accelerating some clinical programs. It also has direct implications for federal revenue and for how companies structure R&D and financing decisions tied to orphan-designated projects.
At a Glance
What It Does
The bill amends Internal Revenue Code section 45C(a) to change the percentage applied when computing the orphan drug tax credit, and makes that change effective for taxable years beginning after the Act’s enactment. It only modifies the statutory percentage; it does not rewrite other eligibility or documentation provisions in section 45C.
Who It Affects
Biopharmaceutical companies conducting qualifying clinical testing for FDA-designated orphan drugs—ranging from small biotech firms to large pharmaceutical sponsors—plus their investors and tax advisors. The Treasury and the Joint Committee on Taxation will see direct budgetary effects from the change.
Why It Matters
Restoring a larger credit raises the marginal subsidy for rare-disease clinical trials, which can change portfolio choices and financing terms for early-stage companies. For policymakers and compliance officers, the change is a targeted tax-law tweak with outsized program-level implications because orphan drug development is costly and concentrated.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
Section 45C of the tax code currently gives a credit tied to certain clinical testing expenses for drugs with orphan designation. That credit reduces a taxpayer’s federal income tax liability dollar-for-dollar and is computed as a percentage of qualifying clinical testing expenditures related to an orphan indication.
Cameron’s Law intervenes only at the formula level: it increases the statutory percentage used in that calculation, thereby raising the face value of the credit for each dollar of qualifying expense.
Because the bill does not alter the definitions, certification criteria, or documentation rules that live elsewhere in section 45C and related guidance, taxpayers will claim the larger credit through the same return positions and supporting materials they use today. The operational work—tracking qualified clinical testing costs, securing orphan designation where required, and maintaining contemporaneous documentation—remains unchanged; the difference is purely in the percentage of those tracked costs that converts into a tax credit.On the practical side, a larger tax credit directly improves cash flow for sponsoring entities at the time they file taxes, which can be especially material for small and mid‑sized companies burning cash on clinical programs.
Tax directors and CFOs will need to update forecasts and models to reflect a higher subsidy rate; tax return preparers should confirm that their expense allocation methods still match IRS expectations because a larger percentage amplifies the tax‑benefit impact of any allocation choices. From the Treasury’s perspective, the change increases projected outlays (in the form of forgone revenue), and absent offsets the bill creates a straightforward fiscal cost.
The Five Things You Need to Know
The bill amends subsection 45C(a) of the Internal Revenue Code by replacing the existing percentage with a higher statutory percentage for computing the orphan drug credit.
The increase applies to taxable years beginning after the date of enactment of the Act; the bill contains no retroactive application to earlier taxable years.
The text alters only the percentage language in section 45C(a) and leaves intact the existing statutory eligibility criteria, definitions, and documentation requirements in section 45C.
The bill contains no accompanying revenue offsets, limitations, or sunset provision—there is no express cap or phase‑out in the bill text.
Sponsors listed on the bill include Rep. Josh Gottheimer with co-sponsors Mr. Bacon, Mr. Panetta, and Mr. Suozzi; the change is narrowly targeted to the orphan-drug credit rather than a broader tax overhaul.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title — 'Cameron's Law'
This short section assigns the bill its popular name. That name has no legal effect on tax administration, but it signals the legislative intent to treat the measure as a focused change tied to orphan-drug incentives.
Substantive change to section 45C(a)
This is the operative amendment. It instructs the Internal Revenue Code to use a higher percentage when computing the orphan drug credit. Practically, that means each dollar of qualifying clinical testing expense will convert into a larger credit amount on the taxpayer’s return. Because the amendment targets only the numeric percentage in subsection (a), it does not disturb the statutory mechanisms that determine which costs qualify or how they must be substantiated.
Effective date: taxable years beginning after enactment
The effective-date clause confines the change to future taxable years starting after the Act becomes law. Taxpayers therefore cannot claim the increased percentage for costs allocated to prior taxable years; companies planning multi-year clinical programs should model the timing of expenditures and expected tax filings to capture the increased credit in affected years.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Small and mid‑sized biotech sponsors: The larger percentage increases after‑tax value of qualifying clinical testing expenditures, improving near‑term cash flow for companies that rely on tax credits to finance trials.
- Investors in orphan-drug programs: Higher expected tax subsidies can improve projected returns and lower financing costs for equity and debt, making some riskier rare‑disease projects more investible.
- Tax advisors and preparers serving life‑sciences clients: Firms will have new work updating modeling, client advisories, and return positions to reflect the larger credit and to optimize timing of qualified expenditures.
Who Bears the Cost
- Federal Treasury / taxpayers at large: The change increases revenue forgone through a larger credit unless Congress enacts offsets; that raises budgetary costs borne by the federal government.
- Large pharmaceutical firms with limited orphan activity: Companies that do not undertake qualifying orphan trials gain little directly while still competing in a market where rivals may receive larger subsidies.
- Tax compliance departments of sponsors: Although the rules for qualification do not change, the larger credit raises stakes around documentation, allocations, and audit exposure, increasing compliance workload and potential legal risk.
Key Issues
The Core Tension
The bill trades a straightforward, administrable incentive for rare‑disease R&D—a larger, easy‑to‑apply tax credit—for potential budgetary cost and weaker control over downstream outcomes: it boosts the quantity of development activity but does not tie that subsidy to drug pricing, affordability, or demonstrated public‑health value, leaving policymakers to choose between simplicity and targeted accountability.
Because the bill makes a single, numeric change inside a longer statutory scheme, many important implementation questions hinge on the existing text and IRS practice rather than on new language. For example, the administrative process for substantiating qualified clinical testing expenses—what records suffice, how costs are allocated across indications or projects, and how joint or collaborative trials are handled—remains controlled by prior law and guidance.
With the credit worth more per dollar, small differences in allocation methods or documentation could produce materially different tax outcomes, increasing audit and controversy risk.
The bill also leaves fiscal consequences unaddressed. It does not include offsets, a sunset, or caps, so the Congressional budget impact depends entirely on how many taxpayers claim the credit at the higher rate and how the Joint Committee on Taxation scores the change.
Policymakers will need to weigh the expected increase in orphan-drug R&D activity against the direct revenue cost. Finally, the measure increases a subsidy that applies regardless of final product price or patient access outcomes; it therefore raises classic policy questions about whether a tax credit is the best tool to steer socially desirable drug development, and whether additional guardrails (targeted eligibility, clawbacks, or price/access conditions) should accompany a larger subsidy.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.